Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2009 1
2010 1
2016 1
2018 1
2020 1
2022 3
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Computational and Experimental Evaluation of the Immune Response of Neoantigens for Personalized Vaccine Design.
Malaina I, Gonzalez-Melero L, Martínez L, Salvador A, Sanchez-Diez A, Asumendi A, Margareto J, Carrasco-Pujante J, Legarreta L, García MA, Pérez-Pinilla MB, Izu R, Martínez de la Fuente I, Igartua M, Alonso S, Hernandez RM, Boyano MD. Malaina I, et al. Among authors: izu r. Int J Mol Sci. 2023 May 19;24(10):9024. doi: 10.3390/ijms24109024. Int J Mol Sci. 2023. PMID: 37240369 Free PMC article.
Graft-versus-lymphoma effect.
Richard C, Bermúdez A, Izu R. Richard C, et al. Among authors: izu r. Br J Haematol. 2010 Apr;149(2):166. doi: 10.1111/j.1365-2141.2009.08001.x. Epub 2009 Dec 8. Br J Haematol. 2010. PMID: 20015300 Free article. No abstract available.
Pirin is a prognostic marker of human melanoma that dampens the proliferation of malignant cells by downregulating JARID1B/KDM5B expression.
Penas C, Arroyo-Berdugo Y, Apraiz A, Rasero J, Muñoa-Hoyos I, Andollo N, Cancho-Galán G, Izu R, Gardeazabal J, Ezkurra PA, Subiran N, Alvarez-Dominguez C, Alonso S, Bosserhoff AK, Asumendi A, Boyano MD. Penas C, et al. Among authors: izu r. Sci Rep. 2023 Jun 12;13(1):9561. doi: 10.1038/s41598-023-36684-2. Sci Rep. 2023. PMID: 37308689 Free PMC article.
Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.
Muniesa C, Gallardo F, García-Doval I, Estrach MT, Combalia A, Morillo-Andújar M, De la Cruz-Vicente F, Machan S, Moya-Martínez C, Rovira R, Sanchez-Gonzalez B, Acebo E, Amutio E, Peñate Y, Losada-Castillo MDC, García-Muret MP, Iznardo H, Román-Curto C, Cañueto J, Fernández-de-Misa R, Flórez Á, Izu RM, Torres-Navarro I, Zayas A, Pérez-Paredes G, Blanes M, Yanguas JI, Pérez-Ferriols A, Callejas-Charavia M, Ortiz-Romero PL, Pérez-Gil A, Prieto-Torres L, González-Barca E, Servitje O. Muniesa C, et al. Among authors: izu rm. J Eur Acad Dermatol Venereol. 2023 Jan;37(1):57-64. doi: 10.1111/jdv.18563. Epub 2022 Sep 9. J Eur Acad Dermatol Venereol. 2023. PMID: 36017748
Melanoma Clinical Decision Support System: An Artificial Intelligence-Based Tool to Diagnose and Predict Disease Outcome in Early-Stage Melanoma Patients.
Diaz-Ramón JL, Gardeazabal J, Izu RM, Garrote E, Rasero J, Apraiz A, Penas C, Seijo S, Lopez-Saratxaga C, De la Peña PM, Sanchez-Diaz A, Cancho-Galan G, Velasco V, Sevilla A, Fernandez D, Cuenca I, Cortes JM, Alonso S, Asumendi A, Boyano MD. Diaz-Ramón JL, et al. Among authors: izu rm. Cancers (Basel). 2023 Apr 6;15(7):2174. doi: 10.3390/cancers15072174. Cancers (Basel). 2023. PMID: 37046835 Free PMC article.
Association of TYR SNP rs1042602 with Melanoma Risk and Prognosis.
Sevilla A, Sánchez-Diez A, Cobo S, Izagirre N, Martinez-Cadenas C, Martí RM, Puértolas T, de Unamuno B, Bañuls J, Izu R, Gardeazabal J, Asumendi A, Boyano MD, Alonso S. Sevilla A, et al. Among authors: izu r. Life (Basel). 2022 Dec 1;12(12):2004. doi: 10.3390/life12122004. Life (Basel). 2022. PMID: 36556369 Free PMC article.
Serum markers improve current prediction of metastasis development in early-stage melanoma patients: a machine learning-based study.
Mancuso F, Lage S, Rasero J, Díaz-Ramón JL, Apraiz A, Pérez-Yarza G, Ezkurra PA, Penas C, Sánchez-Diez A, García-Vazquez MD, Gardeazabal J, Izu R, Mujika K, Cortés J, Asumendi A, Boyano MD. Mancuso F, et al. Among authors: izu r. Mol Oncol. 2020 Aug;14(8):1705-1718. doi: 10.1002/1878-0261.12732. Epub 2020 Jun 24. Mol Oncol. 2020. PMID: 32485045 Free PMC article.
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1).
Daudén E, de la Cueva P, Salgado-Boquete L, Llamas-Velasco M, Fonseca E, Pau-Charles I, Asensio D, Guilà M, Carrascosa JM; DIMESKIN 1 Study investigators. Daudén E, et al. Dermatol Ther (Heidelb). 2023 Jan;13(1):329-345. doi: 10.1007/s13555-022-00863-2. Epub 2022 Dec 1. Dermatol Ther (Heidelb). 2023. PMID: 36456890 Free PMC article.
14 results